Study of GS-9911 With or Without Antibody Treatment for Adults With Solid Tumors

Exclusion Criteria

• •Positive serum pregnancy test or lactating female
• •History of intolerance, hypersensitivity, or treatment discontinuation due to life- threatening immune-related adverse events on prior immunotherapy
• •Receipt of the therapies listed below within the specified timeframe prior to planned Cycle 1 Day 1 including: major surgery (\< 4 weeks), immunotherapy or biologic therapy (\< 28 days), chemotherapy (\< 21 days), targeted small molecule therapy (\<14 days or 5 half-lives, whichever is sooner), hormonal or other adjunctive therapy (\< 14 days), radiation therapy (\< 21 days), live vaccine (\< 28 days)
• •Any prior allogeneic tissue/solid organ transplantation, including allogeneic stem cell transplantation
• •Diagnosis of immunodeficiency, or requires systemic corticosteroids (\> 10 mg of prednisone daily, or equivalent)
• •History of autoimmune disease or active autoimmune disease that has required systemic treatment within 2 years prior to the start of study drug
• •History of pneumonitis requiring treatment with corticosteroids, interstitial lung disease, drug-induced pneumonitis, or severe radiation pneumonitis (excluding localized radiation pneumonitis)
• •Active second malignancy. Note: individuals with a history of malignancy that have been completed treated, with no evidence of active cancer for 2 years prior to enrollment, or individuals with surgically cured tumors with low risk of recurrence are allowed to enroll.
• •Known active central nervous system (CNS) metastases and/or carcinomatous meningitis
• •Symptomatic cardiovascular disease
• •Active serious infection requiring ongoing treatment
• •Active infection with hepatitis B virus (HBV), hepatitis C virus (HCV), or HIV.
• •Symptomatic ascites or pleural effusion